W E EVANS - JoVE Visualize

Showing results (181-190 of 274) with videos related to

Pageof 28

Sort By:

Clinical Pharmacology and Therapeutics|March 1, 1983

Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusionW E Evans, P R Hutson, C F Stewart, et al.

Cancer Treatment Reports|November 1, 1981

Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II studyC B Pratt, A Hayes, A A Green, et al.

Cancer Treatment Reports|January 1, 1980

High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcomaC B Pratt, C Howarth, J L Ransom, et al.

NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemiaW E Evans, M Abromowitch, W R Crom, et al.

Human Molecular Genetics|June 1, 1994

Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeR Saxena, G L Shaw, M V Relling, et al.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 5, 2001

Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drugN F Krynetskaia, J Y Feng, E Y Krynetski, et al.

Medical and Pediatric Oncology|February 1, 1996

Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristicsM Berkovitch, D Matsui, A Zipursky, et al.

Drug Intelligence & Clinical Pharmacy|November 1, 1982

Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemiaW E Evans, C F Stewart, P R Hutson, et al.

Medical and Pediatric Oncology|January 1, 1991

Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugsW E Evans, J H Rodman, M V Relling, et al.

The Journal of Pediatrics|October 1, 1987

Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemiaM L Garré, M V Relling, D Kalwinsky, et al.

Pageof 28

Showing results (181-190 of 274) with videos related to

Sort By:

Pageof 28

Clinical Pharmacology and Therapeutics|March 1, 1983

Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusionW E Evans, P R Hutson, C F Stewart, et al.

Cancer Treatment Reports|November 1, 1981

Pharmacokinetic evaluation of cisplatin in children with malignant solid tumors: a phase II studyC B Pratt, A Hayes, A A Green, et al.

Cancer Treatment Reports|January 1, 1980

High-dose methotrexate used alone and in combination for measurable primary or metastatic osteosarcomaC B Pratt, C Howarth, J L Ransom, et al.

NCI Monographs : a Publication of the National Cancer Institute|January 1, 1987

Clinical pharmacodynamic studies of high-dose methotrexate in acute lymphocytic leukemiaW E Evans, M Abromowitch, W R Crom, et al.

Human Molecular Genetics|June 1, 1994

Identification of a new variant CYP2D6 allele with a single base deletion in exon 3 and its association with the poor metabolizer phenotypeR Saxena, G L Shaw, M V Relling, et al.

FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|September 5, 2001

Deoxythioguanosine triphosphate impairs HIV replication: a new mechanism for an old drugN F Krynetskaia, J Y Feng, E Y Krynetski, et al.

Medical and Pediatric Oncology|February 1, 1996

Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristicsM Berkovitch, D Matsui, A Zipursky, et al.

Drug Intelligence & Clinical Pharmacy|November 1, 1982

Disposition of intermediate-dose methotrexate in children with acute lymphocytic leukemiaW E Evans, C F Stewart, P R Hutson, et al.

Medical and Pediatric Oncology|January 1, 1991

Concept of maximum tolerated systemic exposure and its application to phase I-II studies of anticancer drugsW E Evans, J H Rodman, M V Relling, et al.

The Journal of Pediatrics|October 1, 1987

Pharmacokinetics and toxicity of methotrexate in children with Down syndrome and acute lymphocytic leukemiaM L Garré, M V Relling, D Kalwinsky, et al.

Pageof 28